focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

Mon, 18th Dec 2023 07:55

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Last week saw a rally in stock markets across the globe, thanks to a dovish pivot from the US Federal Reserve, though the FTSE 100 underperformed somewhat. This week, investors will be keeping a close eye on Friday's US personal consumption expenditures price index data - the Fed's preferred metric of inflation.

Another key focal point for the week will be the Bank of Japan's monetary policy decision to be announced on Tuesday.

"There is nothing more than a slim probability for the BoJ to exit negative rates this week, but investors are eager to hear further details about how and when the BoJ will leave the negative rate territory," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 10.4 points, 0.1%, at 7,561.96

----------

Hang Seng: down 1.1% at 16,612.95

Nikkei 225: closed up 0.6% at 32,758.98

S&P/ASX 200: closed down 0.2% at 7,426.40

----------

DJIA: closed up 0.2%, at 37,305.16

S&P 500: closed little changed at 4,719.19

Nasdaq Composite: closed up 0.4% at 14,813.92

----------

EUR: up at USD1.0919 (USD1.0912)

GBP: down at USD1.2689 (USD1.2693)

USD: up at JPY142.26 (JPY141.75)

GOLD: down at USD2,023.33 per ounce (USD2,034.62)

OIL (Brent): up at USD77.31 a barrel (USD76.34)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

10:00 CET Germany Ifo business climate index

09:30 GMT UK card spending statistics

10:00 EST US NAHB housing market index

----------

BROKER RATING CHANGES

----------

Morgan Stanley cuts Fresnillo to 'underweight' (equal-weight) - price target to 540 (620) pence

----------

UBS cuts Barratt Developments to 'neutral' (buy) - price target 610 (495) pence

----------

UBS raises Taylor Wimpey to 'buy' (neutral) - price target 160 (126) pence

----------

COMPANIES - FTSE 100

----------

Spirax-Sarco Engineering named Louisa Burdett as its new chief financial officer, with a starting date of July next year. Burdett is currently CFO at Croda International, and has led finance functions at "several large companies" including Meggitt and Victrex. Spirax-Sarco said CFO Nimesh Patel, who was previously announced to be its new CEO, will take the helm of the firm on January 16. Group finance director, Phil Scott, will be interim CFO from that date until Burdett joins the company. Croda International noted Burdett's departure, and said it has begun the search for her successor. Additionally, Croda said adjusted pretax profit was likely to come at the lower end of its guidance of GBP300 million to GBP320 million range, mostly due to recent currency movements, especially in Argentina.

----------

GSK announced positive headline results from the second part of its phase III trial of Jemperli plus standard-of-care chemotherapy, followed by dostarlimab plus Zejula as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer. "The trial, which evaluated this combination against placebo plus chemotherapy followed by placebo, met its primary endpoint of progression-free survival, with a statistically significant and clinically meaningful benefit observed in both the overall patient population and in a subpopulation of patients with mismatch repair proficient/microsatellite stable tumours," GSK explained.

----------

The Financial Times reported that GSK is looking for some new deals in China. This comes after GSK rebuilt a "very strong" relationship with the government and local companies since a corruption scandal a decade ago, the newspaper said. Chief Commercial Officer Luke Miels told the FT that GSK is working on further deals with Chinese companies after it signed a licensing agreement in October worth up to USD1.5 billion for a cancer drug developed by Hansoh Pharmaceutical Group.

----------

Frasers Group is in talks to buy Matchesfashion, a luxury clothing retailer, from its private equity owner since 2017, Apax Partners, Sky News reported on Saturday. Citing "City sources", Sky said Frasers is among a small group of bidders that submitted offers early last week. Frasers would likely pay in excess of GBP50 million for Matchesfashion, whose business has struggled, according to Sky, citing an "insider". Sky said fellow London-listed retailer Next also is said to have expressed an interest in buying Matchesfashion.

----------

COMPANIES - FTSE 250

----------

Games Workshop has entered an agreement with Amazon's Content Services subsidiary for the prospective development of its Warhammer 40,000 universe into films and television series, alongside the associated merchandising rights. The deal grants exclusive rights to Amazon for film and TV series set within the universe, as well as an option for exclusive rights in the Warhammer Fantasy universe down the line. "Games Workshop and Amazon will work together for a period of 12 months to agree creative guidelines for the films and television series to be developed by Amazon. The agreement will only proceed once the creative guidelines are mutually agreed between Games Workshop and Amazon," the UK company said. It added that it will make no change to its forecast for its financial year ending in June. Games Workshop had announce an agreement in principle with Amazon in December last year.

----------

IP Group has launched a share buy back for up to GBP20 million. The intellectual property investor said the programme came in light of the discount of its share price to its net asset value per share, and it determined now to be "an appropriate time".

----------

OTHER COMPANIES

----------

Hollywood Bowl held its annual dividend unchanged and announced plans for a share buyback worth up to GBP10 million. The operator of ten-pin bowling centres reported pretax profit of GBP45.1 million for the financial year that ended September 30, down from GBP46.7 million in financial 2022, which benefited from a reduced rate of value-added tax on bowling.

----------

Canadian Overseas Petroleum said its non-binding Cole Creek joint venture letter of intent has been terminated, and it plans "no further discussions at this stage". Back in July, COPL had announced the potential joint venture with "an established energy company" to develop and exploit oil reserves at the Cole Creek in Converse and Natrona counties, Wyoming. "The company will provide a further update before year end regarding its strategy relating to the development of its Cole Creek and Barron Flats Shannon Units," COPL said on Monday.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.